Read Larry Connors' blog – Short Term Trading Strategies
SAN MATEO, Calif., March 30, 2009 (GLOBE NEWSWIRE) -- BioForm Medical, Inc. (Nasdaq:BFRM) today announced it has, over the course of its current fiscal year, strengthened its Board of Directors with the addition of three seasoned executives with significant aesthetics industry experience. Chris Dennis, former Global President of OrthoNeutrogena, joined the Board of Directors in December 2008. Jeff Nugent, former CEO of Revlon and former Worldwide President and CEO of Neutrogena, joined the Board of Directors in February 2009. In addition, Dennis Condon, currently BioForm Medical's President and Chief Business Officer, and formerly a member of BioForm Medical's Board of Directors, has rejoined the Board of Directors in March 2009.
In evaluating and proposing nominees for election to the Board, BioForm Medical's Nominating and Corporate Governance Committee has guided the Board of Directors' transition from a predominantly venture capital-led to one led by industry veterans. Pursuant to this initiative, Jeff Nugent has replaced Dr. Albert Cha, a Managing Partner at Vivo Ventures, an early BioForm Medical investor, and Chris Dennis has replaced Dr. Evan Melrose, a Managing Partner of PTV Sciences, also an early BioForm Medical investor.
Chris Dennis is currently serving as an independent consultant to medical technology companies and most recently served as the Senior Vice President of Commercial Operations for Angiotech Pharmaceuticals, Inc. Mr. Dennis brings to BioForm Medical significant dermatology, medical aesthetics, and pharmaceutical industry expertise. Mr. Dennis previously held a number of senior management positions within various subsidiaries at Johnson & Johnson for over 17 years in marketing, sales and general management. Prior to joining Angiotech, Mr. Dennis was Global President of OrthoNeutrogena, a Johnson & Johnson company, where he was responsible for overall strategy and business growth initiatives.
Since May 2007, Jeff Nugent has served as the President and CEO of Ventus Medical, a privately-held medical device company focused on the development of a treatment for obstructive sleep apnea. Mr. Nugent also serves on the boards of directors of two privately-held medical aesthetics companies and is the Chairman of the board of directors of TRIA Beauty. Mr. Nugent brings to BioForm Medical significant experience and expertise in the medical aesthetics and consumer aesthetics markets. Most notably, Mr. Nugent served as President and CEO of Revlon from 1999 to 2002. Mr. Nugent previously held a number of senior management positions within Johnson & Johnson for over 20 years in R&D, operations, marketing and finance. Mr. Nugent served as Worldwide President and CEO of Neutrogena from the time of its acquisition by Johnson & Johnson through the first five years of its considerable growth as a global leader in professionally-recommended skin care.
Since June 2007, Dennis Condon has been BioForm Medical's President and Chief Business Officer and previously served as a member of BioForm Medical's Board of Directors from January 2004 to June 2007. From March 2006 to June 2007, he was the CEO and President of Apsara Medical, a medical device company focused on the aesthetics market. From February 2005 to November 2005, Mr. Condon was the President and CEO of Reliant Technologies Inc., a provider of lasers for aesthetic applications. Prior to joining Reliant Technologies, Mr. Condon was CEO of The Plastic Surgery Company, a healthcare services company and was President of Mentor's aesthetics division.
"We are delighted that Mr. Dennis, Mr. Nugent, and Mr. Condon have joined our Board of Directors at this important point in the Company's development. BioForm Medical is working diligently to weather the macroeconomic downturn and to position the business for rapid growth and profitability in a recovery. We have the opportunity to be a leader in the medical aesthetics industry, and our new Board members' industry expertise will be invaluable as we develop our strategies to build the company in the coming years," said Steve Basta, CEO of BioForm Medical. "We thank Dr. Albert Cha and Dr. Evan Melrose for their years of dedicated service and guidance."
About BioForm Medical, Inc.:
BioForm Medical, Inc. is a medical aesthetics company headquartered in San Mateo, California, developing products that enhance aesthetic procedures performed in dermatology and plastic surgery practices. BioForm Medical's lead product is RADIESSE(r) dermal filler, a long-lasting filler for use in facial aesthetics. BioForm Medical is developing several future aesthetics products, including a radiofrequency treatment to reduce nerve function in the forehead, a sclerotherapy treatment for spider veins, and a surgical adhesive for brow lifts. For more information about BioForm Medical, please visit www.bioform.com.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: BioForm Medical, Inc.
BioForm Medical, Inc.
Can Gumus, Senior Manager, Corporate Development
650.286.4003
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.